Recently published in NEJM (New England Journal of Medicine) is an article about antisense oligonucleotides. It's a new drug that reduces Lp(a) or lipoprotein (a) by up to 80%. This is more promising than current treatments, including niacin, L-carnitine, and apheresis. Still, the new antisense drug appears to be not yet ready for primetime. Here's the link to the NEJM article: https://www.nejm.org/doi/full/10.1056/NEJMoa1905239
For more information, contact us at 859-721-1414 or myhealth@prevmedheartrisk.com. Also, check out the following resources: